Is targeted therapy feasible in acute myelogenous leukemia?

Heiko Konig, Mark Levis

Research output: Contribution to journalReview articlepeer-review


The prognosis for patients with acute myeloid leukemia (AML) is determined to a large degree by the biology of the leukemic cell. In recent years, the identification and characterization of genetic aberrations has vastly improved our understanding of the pathogenesis of AML. In contrast, however, there has been a lack of clinically meaningful therapeutic advances. The same chemotherapeutic strategies have been applied to AML for several decades now, and while these regimens are effective in inducing remission, most patients relapse within months after initial treatment. Hence, there is an urgent need for novel therapies. We review herein a number of lines of laboratory and clinical trial data supporting the clinical value of targeted treatment approaches that will likely result in improved outcomes for patients with AML.

Original languageEnglish (US)
Pages (from-to)118-127
Number of pages10
JournalCurrent Hematologic Malignancy Reports
Issue number2
StatePublished - Jun 2014


  • Acute myelogenous leukemia
  • Chemotherapeutic strategies
  • Molecular markers
  • Pathogenesis
  • Relapse

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research


Dive into the research topics of 'Is targeted therapy feasible in acute myelogenous leukemia?'. Together they form a unique fingerprint.

Cite this